Canertinib (CI-1033)

別名：PD183805

製品コード：S1019 純度：99.99%

Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.

CAS No. 267243-28-7

サイズ	価格(税別)	在庫状況
10mg	JPY 22000	国内在庫あり
25mg	JPY 37000	国内在庫あり
1g	JPY 285000	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（46）

製品安全説明書

現在のバッチを見る：純度： 99.99%

99.99

Canertinib (CI-1033)関連製品

関連ターゲット	EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR	もっと見る
関連製品	AG-490 AG-1478 Rociletinib (CO-1686) WZ4002 Genistein Poziotinib PD153035 PD153035 HCl Allitinib tosylate AEE788 (NVP-AEE788) Pelitinib (EKB-569) Canertinib dihydrochloride Varlitinib Icotinib (BPI-2009H) Nazartinib (EGF816) NSC228155 PD168393 Olmutinib (BI 1482694) Zorifertinib (AZD3759) AZ5104 Lazertinib CL-387785 (EKI-785) TAK-285 Daphnetin Pyrotinib dimaleate Alflutinib (Furmonertinib) mesylate EGFR Inhibitor Chrysophanic Acid Norcantharidin WZ8040 Butein Cyasterone Avitinib (Abivertinib) CNX-2006 MTX-211 Naquotinib(ASP8273) Tuxobertinib (BDTX-189) WZ3146 Sunvozertinib (DZD9008) Tyrphostin 9 EAI045 zipalertinib (TAS6417) Almonertinib (HS-10296) AG-18	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library Tyrosine Kinase Inhibitor Library PI3K/Akt Inhibitor Library Cell Cycle compound library Angiogenesis Related compound Library	もっと見る

シグナル伝達経路

EGFRシグナル伝達経路

EGFR阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
human A431 cells	Function assay	1 μM	1 h	Irreversible inhibition of EGFR autophosphorylation in human A431 cells at 1 uM incubated for 1 hr followed by compound wash out measured 5 hrs post EGF addition by Western blotting analysis	24900594
human LNCaP cells	Function assay	10 μM	2 h	Inhibition of autophosphorylation of immunoprecipitated flag-tagged Bmx expressed in human LNCaP cells assessed as incorporation of [32P]ATP at 10 uM pretreated for 2 hrs before transfection by immunoblot analysis	18667312
human HCC827 cells	Proliferation assay		72 h	Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay, IC50=0.001 μM	22339342
human BT474 cells	Proliferation assay		3 days	Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining, EC50=0.01 μM	19028424
human HN5 cells	Proliferation assay		3 days	Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining, EC50=0.05 μM	19028424
human NCI-H1975 cells	Proliferation assay		72 h	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay, IC50=0.064 μM	22339342
human A431 cells	Proliferation assay		72 h	Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay, IC50=0.15 μM	22339342
human A549 cells	Proliferation assay		72 h	Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay, IC50=1.59 μM	22339342
human HL7702 cells	Proliferation assay		72 h	Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay, IC50=2.3 μM	22339342
NCI-H1975 cells	Growth inhibition assay		48 h	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay	24900594
A431 cells	Function assay			Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting, IC50=0.0074 μM	10753475
MDA-MB 453 cells	Function assay			Inhibition of autophosphorylation of ERBB2 receptor kinase in MDA-MB 453 cells, IC50=0.009 μM	10753475
mouse BAF3 cells	Function assay			Inhibition of Blk expressed in mouse BAF3 cells assessed as cytotoxicity, IC50=0.029 μM	18667312
mouse BAF3 cells	Function assay			Inhibition of JAK3 expressed in mouse BAF3 cells assessed as cytotoxicity， IC50=2 μM	18667312
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.

特性

First kinase inhibitor to show irreversible activity and to have entered clinical trials (serving as a template for further development).

Targets

EGFR ^[1] (Cell-free assay)	ErbB2 ^[1] (Cell-free assay)
1.5 nM	9.0 nM

In Vitro
In vitro	CI-1033 shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB 453 cells. CI-1033 also shows high permeability in Caco-2 cells. ^[1] CI-1033 alone, significantly suppresses constitutively activated Akt and MAP kinase. CI-1033 in combination inhibits Akt and prevents increased levels of MAPK phosphorylation. CI-1033 stimulates p27 expression and p38 phosphorylation in MDA-MB-453 cells. ^[2] CI-1033 is highly specific to the erbB receptor family and not sensitive to PGFR, FGFR or IR even at 50 μM. CI-1033 shows high levels of inhibition in A431 cells expressing EGFR with IC50 of 7.4 nM. CI-1033 suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively. CI-1033 also inhibits expression of pp62^c-fos in response to heregulin. ^[3] CI-1033 is predicted to modify Cys773 covalently within the ATP binding site of the HER2 kinase and enhances destruction of both mature and immature ErbB-2 molecules. ^[4] CI-1033 induces a significant decrease in measurable phosphorylation of tyrosine residues 845 and 1068 of EGFR, which are responsible for Src and Ras/MAPK signaling respectively. The corresponding residues of Her-2, tyrosine residues 877 and 1248 are dephosphorylated significantly by CI-1033 at a concentration of 3 μM or higher. CI could block EGFR internalization and increase the rate of apoptosis in primary osteosarcoma cells in a titratable fashion. ^[5] In addition, CI-1033 inhibits the proliferation of TT, TE2, TE6 and TE10 cells significantly at 0.1 nM. ^[6]
Kinase Assay	Tyrosine Kinase Assays
Kinase Assay	Enzyme assays for determination of IC50 are performed in 96-well filter plates in a total volume of 0.1 mL, containing 20 mM Hepes, pH 7.4, 50 mM sodium vanadate, 10 μM the ATP containing 0.5 mCi of [³²P]ATP, 20 mg of polyglutamic acid/tyrosine, 10 ng of EGFR tyrosine kinase, and appropriate dilutions of CI-1033. All components except the ATP are added to the well and the plate is incubated with shaking for 10 min at 25 °C. The reaction is started by adding [³²P]ATP, and the plate is incubated at 25 °C for another 10 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate is kept at 4 °C for at least 15 min to allow the substrate to precipitate. The wells are then washed five times with 0.2 mL of 10% TCA and 32P incorporation determined with a Wallac β plate counter.
細胞実験	細胞株	TT, TE2, TE6 and TE10 cells
	濃度	0.1-5.0 nM
	反応時間	1, 3, 5 and 7 days
	実験の流れ	Cells (1 × 10⁴) are seeded in each well of a 24-well plastic culture plate and left overnight in DMEM or RPMI-1640 supplemented with 10% FBS. The next morning, the cells are treated with the indicated concentrations of CI-1033 (0.1-5.0 nM) for varying periods (1, 3, 5 and 7 days). After treatment, the cells are counted using a Coulter counter. The percent of cell proliferation is calculated by this formula: treatment cell number/control cell number × 100 for each time period.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	pEGFR / EGFR / p-HER2 / HER2 / p-HER3 / HER3 / MUC4 p-FAK / FAK / p-AKT / AKT		25686822
	Growth inhibition assay	Cell viability		28638122

In Vivo
In Vivo	CI-1033 shows impressive activity against A431 xenografts in nude mice at 5 mg/kg of body weight. ^[1] CI-1033 (20 to 80 mg/kg/d) achieves a high degree of tumor regressions in H125 xenograft models. ^[3] Oral administration of CI-1033 causes a marked inhibition of growth in TT, TE6 and TE10 xenografts in nude mice, without animal death and <10% weight loss. ^[6]
動物実験	動物モデル	A431 xenografts established in nude mice
	投与量	~18 mg/kg
	投与経路	Administered orally

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT00050830	Completed	Lung Neoplasms	Pfizer	January 2003	Phase 2
NCT00174356	Completed	Carcinoma Non-Small Cell Lung	Pfizer	December 2002	Phase 1
NCT00051051	Completed	Breast Neoplasms	Pfizer	December 2002	Phase 2

参考
[1] Smaill JB et al. J Med Chem. 2000; 43(7): 1380-1397. [2] Nelson JM et al. J Biol Chem. 2001; 276(18): 14842-14827. [3] Slichenmyer WJ et al. Semin Oncol. 2001; 28(5 Suppl 16): 80-85. [4] Citri A et al. EMBO J. 2002; 21(10): 2407-2417. [5] Hughes DP et al. Pediatr Blood Cancer. 2006; 46(5): 614-623. [6] Ako E et al. Oncol Rep. 2007; 17(4): 887-893. [7] Erlichman C, et al. Cancer Res, 2001, 61(2), 739-748. + 展開

参考

+ 展開

化学情報

分子量	485.94	化学式	C₂₄H₂₅ClFN₅O₃
CAS No.	267243-28-7	SDF	Download Canertinib (CI-1033) SDFをダウンロードする
Smiles	C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

4-Methylpyridine : 100 mg/mL

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

よくある質問（FAQ）

質問1:
I would like to know which is the best option/solvent to dilute CI-1033 (Catalog No.S1019) for in vivo experiments. (I am treating mice at 30mg/mL of CI-1033.)

回答
The compound in the formulation recommended (30% Propylene glycol, 5% Tween 80, 65% D5W) on our product page at 30mg/ml is suspension. It’s fine for oral gavage.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):